TRUQAP

This brand name is authorized in Austria, Estonia, France, Lithuania, Romania, United Kingdom, United States

Active ingredients

The drug TRUQAP contains one active pharmaceutical ingredient (API):

1 Capivasertib UNII WFR23M21IE - CAPIVASERTIB

Capivasertib is a potent, selective inhibitor of the kinase activity of all 3 isoforms of serine/threonine kinase AKT (AKT1, AKT2 and AKT3). AKT activation in tumours is a result of upstream activation from other signalling pathways, mutations of AKT1, loss of Phosphatase and Tensin Homolog (PTEN) function and mutations in the catalytic subunit of PI3K (PIK3CA). Capivasertib reduces growth of cell lines derived from solid tumours and haematological disease, including breast cancer cell lines with and without PIK3CA or AKT1 mutations, or PTEN alterations. Read about Capivasertib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TRUQAP Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC
TRUQAP Film-coated tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EX27		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX27

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3081529, 3081530
Country: FR	Base de données publique des médicaments	Identifier(s): 65968984, 68102912
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1100042, 1100043
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W70411001, W70412001
Country: US	FDA, National Drug Code	Identifier(s): 0310-9500, 0310-9501